The International Neuromodulation Society

The Fastest-Growing, Worldwide Multidisciplinary Body Devoted to Building Knowledge of Neuromodulation

The International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation – the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body. The San Francisco-based INS was formed in 1989 and educates and promotes the field through meetings, its peer-reviewed journal Neuromodulation: Technology at the Neural Interface, explanatory content, and chapter websites. The INS also provides information for patients and produces rolling news briefs about this rapidly evolving field.

The INS Peer-Reviewed Journal – 8 Issues a Year

The INS journal Neuromodulation: Technology at the Neural Interface has a growing Impact Factor and is indexed in Index Medicus, MEDLINE and Pubmed from its first issue in 1998. Members may log in to the members-only section to read the journal online.

journal cover

+Submit a Manuscript.+

Medical Professionals can learn about various considerations concerning neuromodulation and clinic contacts. Once your preliminary questions have been answered, please use the Contact Us facility to find out more and to discuss specific objectives. Others may simply wish to join the INS and one of its related chapter societies, please use the Membership Application.

Clinical trials that involve a wide range of emerging neuromodulation approaches are listed on our Research page. Neuromodulation clinical trials address symptom control through nerve stimulation in such condition categories as:

If you are not a medical professional and you are searching for information about neuromodulation and how these types of treatment could benefit a specific condition such as treatment-resistant headache or other chronic pain syndromes, you may find the sections titled Therapies, About Neuromodulation or FAQs particularly helpful.

Members may log in and visit the members-only section’s Global Discussion Forum

What is Neuromodulation?

Breaking News Share

Researchers: Brain-Computer Interface Aided Motor Recovery from Stroke

June 20, 2018 - Researchers in Switzerland report in Nature Communications that stroke survivors with partial arm paralysis made more progress when functional electrical stimulation of their affected hand was timed to coincide with their intent to move as detected by a brain-computer interface (BCI), compared to a control group that received hand-muscle stimulation that was not timed to coincide with the detectable brain activity. Overall 27 patients participated. Significant improvement was seen in the group that had BCI-directed stimulation after 10 hour-long sessions. The authors report that in the BCI-directed group, EEGs showed increased connections in the motor cortex of the damaged brain hemisphere, noting that at a six-month followup, the functional improvement continued. (EurekAlert)

Study: Deep Brain Stimulation to the Fornix Appears to Slow Progression of Mild Alzheimer's Disease in Older Patients

June 19, 2018 - In a Phase II clinical trial of deep brain stimulation to the fornix for mild Alzheimer's disease, an analysis shows that patients over age 65 benefited the most by appearing to have a slower progression of the disease. In the study, 42 patients were implanted, and after a 12-month randomization period in which half the patients did not receive simulation, all the patients had their electrodes turned on and were followed for another 12 months. (Medical Xpress)

Findings Suggest Non-Invasive Brain Stimulation May Help Improve Disorders of Consciousness

June 18, 2018 - Disorders of consciousness might be improved by non-invasive brain stimulation, suggests an expert who spoke at the 4th Congress of the European Academy of Neurology in Lisbon. In a study, his research group found the extent of impairment fluctuated when they scored coma ratings four times a day. They saw improvements after a session of transcranial direct current stimulation, with improvement lasting up to a week after five consecutive daily stimulation sessions. (

Company Updates Anticipated FDA Submission Timeframe

June 18, 2018 - Helius Medical Technologies, Inc. now expects to submit its request to the FDA for de novo classification and 510(k) clearance in the third quarter of 2018. The company met with the FDA in April through the agency's pre-submission program and plans to meet again in July. The company's investigational device, the Portable Neuromodulation Stimulator, provides non-invasive cranial nerve stimulation, through use of a component that rests on the tongue, with physical and cognitive therapy to regain lost neurological function. (Globe Newswire)

To see select neuromodulation news by category, as well as news about the INS in particular, please visit the Newsroom. To see archived news briefs dating back to January 2011, visit the News Archive.

Continue Reading News Briefs
Last Updated on Monday, December 12, 2016 10:01 AM